Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность Пронорана у пациентов с болезнью Паркинсона
Эффективность Пронорана у пациентов с болезнью Паркинсона
Пилипович А.А. Эффективность Пронорана у пациентов с болезнью Паркинсона. Consilium Medicum. 2014; 16 (9): 5–10.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
2. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur
J Pharmacol 1996; p. 63–7.
3. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75.
4. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
5. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
6. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876–87.
7. Федорова Н. В., Артемьева Е.Г. Применение пронорана – современного агониста дофаминовых рецепторов в лечении болезни Паркинсона. Информационное письмо. М., 2003.
8. Ziegler M, Rascol O. Efficacy of piribedil in adjunction to L-dopa in a 6-month rundomized placebo-controlled study in early Parkinson’s diseases. 52 Annual Meeting of the American Academy of Neurology. San Diego, 2000; Abstract.
9. Allain H, Coz F, Del Signore S et al. Piribedil Plasma Levels after Chronic Oral Administration of Trivastal Retard 50 (150 mg/day) in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 51.
10. Ziegler M, Del Signore S, Bonhomme C et al. Resting Tremor is Inversely Related to Piribedil Plasma Concentration after Intravenous Administration in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 75.
11. Agnoli A, Baldassarini M, Del Roscio et al. Piribedil and Parkinson’s disease: Protection of Peripheral Side-Effects by Domperidone. Apomorphine and Other Dopaminagonistics. Clin Pharmocol 1981; 2: 117–22.
12. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239: 28–34.
13. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
14. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
15. Salazar T. Efficacy of piribedil in adjunction to L-dopa in Parcinson’s disease. Venezuelian experience. 6th International Congress on Parkinson’s Disease and Movement disorders. Barcelona, June 2000; Abstract.
16. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44: 35–44.
17. Engel J, Granerus A, Savanborg A. Piribedil in Parkinson’s syndrome: a clinical study. Eur J Clin Pharmacol 1975; 8: 223–6.
18. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журн. 2006; 11: 27–32.
19. Яхно Н.Н., Захаров В.В.. Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ.) Неврологический журн. 2012; 4: 49–55.
20. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
21. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 23: 13–6.
22. Pirozzolo FJ, Hansch EC, Mortimer JA et al. Dementhia in Parkinson’s diseases: a neuropsychological analysis. Brain Cogn 1982; 1: 71–83.
23. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s diseases: community based study. Mov Disord 1999; 14: 71–83.
24. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
25. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
26. Steriade M, Gloor P, Llinas R et al. Basic mechanisms of cerebral rhythmic activities. Electroencephalogr Clin Neurophysyol 1990; 76: 481–508.
2. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur
J Pharmacol 1996; p. 63–7.
3. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75.
4. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
5. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
6. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876–87.
7. Федорова Н. В., Артемьева Е.Г. Применение пронорана – современного агониста дофаминовых рецепторов в лечении болезни Паркинсона. Информационное письмо. М., 2003.
8. Ziegler M, Rascol O. Efficacy of piribedil in adjunction to L-dopa in a 6-month rundomized placebo-controlled study in early Parkinson’s diseases. 52 Annual Meeting of the American Academy of Neurology. San Diego, 2000; Abstract.
9. Allain H, Coz F, Del Signore S et al. Piribedil Plasma Levels after Chronic Oral Administration of Trivastal Retard 50 (150 mg/day) in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 51.
10. Ziegler M, Del Signore S, Bonhomme C et al. Resting Tremor is Inversely Related to Piribedil Plasma Concentration after Intravenous Administration in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 75.
11. Agnoli A, Baldassarini M, Del Roscio et al. Piribedil and Parkinson’s disease: Protection of Peripheral Side-Effects by Domperidone. Apomorphine and Other Dopaminagonistics. Clin Pharmocol 1981; 2: 117–22.
12. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239: 28–34.
13. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
14. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
15. Salazar T. Efficacy of piribedil in adjunction to L-dopa in Parcinson’s disease. Venezuelian experience. 6th International Congress on Parkinson’s Disease and Movement disorders. Barcelona, June 2000; Abstract.
16. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44: 35–44.
17. Engel J, Granerus A, Savanborg A. Piribedil in Parkinson’s syndrome: a clinical study. Eur J Clin Pharmacol 1975; 8: 223–6.
18. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журн. 2006; 11: 27–32.
19. Яхно Н.Н., Захаров В.В.. Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ.) Неврологический журн. 2012; 4: 49–55.
20. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
21. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 23: 13–6.
22. Pirozzolo FJ, Hansch EC, Mortimer JA et al. Dementhia in Parkinson’s diseases: a neuropsychological analysis. Brain Cogn 1982; 1: 71–83.
23. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s diseases: community based study. Mov Disord 1999; 14: 71–83.
24. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
25. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
26. Steriade M, Gloor P, Llinas R et al. Basic mechanisms of cerebral rhythmic activities. Electroencephalogr Clin Neurophysyol 1990; 76: 481–508.
Авторы
А.А.Пилипович
Кафедра нервных болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Кафедра нервных болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.